Device Trial Radar · NCT07234500
Evaluation of a Mobile Application Designed to Support Type 1 Diabetic Patients in Adjusting Their Insulin Doses.
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Sep 1, 2025
Primary completion
Jun 30, 2026
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- University of BaghdadAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Title: Evaluating a Mobile Application for Insulin Management in Iraqi Type 1 Diabetes Patients. The goal of this clinical trial is to determine whether a mobile health application can improve insulin management and blood sugar control in Iraqi patients with Type 1 Diabetes aged over 15 years who are on intensive insulin therapy. The main question it aims to answer is: Does the use of the mobile application lead to a greater reduction in HbA1c levels compared to standard care alone? Researchers will compare the group using the mobile application to the group receiving standard care alone to see if the application is more effective at improving glycemic control. Participants will be assigned to one of two groups for the 3-month study. Either use the mobile application to guide their daily insulin dose adjustments alongside standard care, or receive standard care alone. Undergo blood tests (including HbA1c) and complete questionnaires about hypoglycemic events, insulin adherence, and quality of life.
Conditions
- Type One Diabetes Mellitus
Interventions
mHealth Mobile ApplicationDevice
This is a culturally and linguistically tailored mobile health (mHealth) application designed for Arabic-speaking patients with Type 1 Diabetes in Iraq. The core function is to assist in calculating precise pre-meal insulin bolus doses by integrating: (1) carbohydrate intake, (2) current blood glucose level, and (3) planned physical activity. Key tailored features include: a database of common Arabic cuisine for easy carbohydrate counting using food photographs (aiding patients with low health literacy), full Arabic language support, and algorithms calibrated for insulin types available in the Iraqi market. The app automatically calculates personalized insulin-to-carbohydrate ratios and correction factors based on the patient's total daily insulin dose, removing the need for manual entry and complex calculations.
Standard Care (in control arm)Other
Routine clinical management for type 1 diabetes, including regular insulin dose adjustments based on standard practice (e.g., clinic visits, HbA1c monitoring).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Hemoglobin (HbA1c)Time frame: Baseline (Day 0) and Post-intervention (Month 3)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Faiha Specialized Diabetes, Endocrine and Metabolism Center at Al-Faiha Teaching hospital
Basra, Basrah, Iraq
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.